Inside these posts: Taxotere

Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.


Hospira shares rise after Sanofi cancer drug OK’d

Hospira won approval for the first U.S. generic version of Sanofi-Aventis SA’s big-selling Taxotere cancer drug, sending Hospira shares up 2 percent.

U.S. sales of Taxotere, an infused chemotherapy known generically as docetaxel, were $1.2 billion last year, according to Hospira. JPMorgan analyst Chris Schott said recently that U.S. approval of generic Taxotere was the most important near-term catalyst for Hospira’s shares. Get the full story »